Nir Peled
#166,165
Most Influential Person Now
Nir Peled's AcademicInfluence.com Rankings
Nir Peledphilosophy Degrees
Philosophy
#9794
World Rank
#13404
Historical Rank
Logic
#6751
World Rank
#8298
Historical Rank
Nir Peledbiology Degrees
Biology
#13479
World Rank
#17024
Historical Rank
Immunology
#930
World Rank
#954
Historical Rank
Download Badge
Philosophy Biology
Nir Peled's Degrees
- Doctorate Medicine Tel Aviv University
- PhD Immunology Tel Aviv University
Why Is Nir Peled Influential?
(Suggest an Edit or Addition)Nir Peled's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. (2016) (6764)
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer (2018) (3740)
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. (2019) (907)
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. (2018) (816)
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry (2019) (627)
- Volatile organic compounds of lung cancer and possible biochemical pathways. (2012) (624)
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2020) (470)
- Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC (2018) (445)
- Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules (2016) (349)
- Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. (2020) (297)
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. (2017) (259)
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations (2016) (252)
- Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. (2019) (239)
- Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. (1999) (226)
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021) (219)
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. (2017) (219)
- Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors (2017) (187)
- The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. (2016) (174)
- Classification of lung cancer histology by gold nanoparticle sensors. (2012) (163)
- Non-invasive Breath Analysis of Pulmonary Nodules (2012) (158)
- Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles. (2009) (156)
- ESR/ERS white paper on lung cancer screening (2015) (152)
- Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. (2019) (148)
- Melatonin Effect on Seizures in Children with Severe Neurologic Deficit Disorders (2001) (144)
- Silicon Nanowire Sensors Enable Diagnosis of Patients via Exhaled Breath. (2016) (142)
- Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. (2015) (142)
- Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. (2012) (132)
- Swimming-induced pulmonary edema: clinical presentation and serial lung function. (2004) (129)
- The association of OSA with insulin resistance, inflammation and metabolic syndrome. (2007) (124)
- BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check‐Point Inhibitors (2018) (121)
- Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. (2016) (119)
- Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations (2010) (117)
- Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) (116)
- Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. (2017) (110)
- Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189. (2021) (109)
- Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel (2019) (109)
- Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling (2017) (107)
- Ambulatory rehabilitation improves exercise capacity in patients with pulmonary hypertension. (2011) (103)
- Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. (2016) (99)
- Interactions between hypoglycemia and sleep architecture in children with type 1 diabetes mellitus. (2003) (99)
- Volatile fingerprints of cancer specific genetic mutations. (2013) (94)
- Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers (2018) (94)
- Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models (2017) (92)
- Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. (2017) (90)
- Contributions of hypoxia and respiratory disturbance index to sympathetic activation and blood pressure in obstructive sleep apnea syndrome. (1998) (84)
- Melatonin improves sleep-wake patterns in psychomotor retarded children. (2000) (83)
- ESR/ERS statement paper on lung cancer screening (2020) (81)
- OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50% (2017) (80)
- Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation (2009) (79)
- LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50% (2020) (78)
- Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer (2013) (78)
- Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (2020) (77)
- Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer (2016) (76)
- Is Local Excision After Complete Pathological Response to Neoadjuvant Chemoradiation for Rectal Cancer an Acceptable Treatment Option? (2010) (76)
- Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects (2017) (73)
- Detection of volatile organic compounds in cattle naturally infected with Mycobacterium bovis (2012) (72)
- ALK‐Rearranged Non–Small‐Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism (2017) (72)
- PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers (2019) (71)
- Peripheral Arterial Stiffness and Endothelial Dysfunction in Idiopathic and Scleroderma Associated Pulmonary Arterial Hypertension (2009) (70)
- Screening for lung cancer: time for large-scale screening by chest computed tomography (2014) (68)
- Prevalence and risk of sleep disturbances in adolescents after minor head injury. (2003) (65)
- New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. (2010) (64)
- Clinical Impact of Hybrid Capture–Based Next‐Generation Sequencing on Changes in Treatment Decisions in Lung Cancer (2017) (63)
- ESR/ERS white paper on lung cancer screening (2015) (62)
- Peripheral endothelial dysfunction in patients with pulmonary arterial hypertension. (2008) (60)
- KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. (2019) (60)
- Detection of Lung Cancer and EGFR Mutation by Electronic Nose System (2017) (57)
- Effect of Melatonin on Seizure Frequency in Intractable Epilepsy (2012) (57)
- Long-term follow-up of untreated patients with sleep apnoea syndrome. (2002) (56)
- MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. (2017) (55)
- Impaired respiratory response to resistive loading during sleep in healthy offspring of patients with obstructive sleep apnea. (1997) (55)
- Mortality of patients with antibiotic-associated diarrhoea: the impact of Clostridium difficile. (2008) (55)
- Predicting Clostridium difficile Toxin in Hospitalized Patients With Antibiotic-Associated Diarrhea (2007) (54)
- MAGE A3 antigen-specific cancer immunotherapeutic. (2009) (54)
- Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. (2017) (53)
- Increased erythrocyte adhesiveness and aggregation in obstructive sleep apnea syndrome. (2008) (51)
- Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer (2019) (49)
- Use of Amplatzer device for endobronchial closure of bronchopleural fistulas. (2008) (48)
- IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). (2018) (48)
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC). (2019) (48)
- Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. (2008) (48)
- Increased Risk for Cancer in Young Patients with Severe Obstructive Sleep Apnea (2018) (45)
- An association between oxygen desaturation and D-dimer in patients with obstructive sleep apnea syndrome (2005) (45)
- Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe (2020) (44)
- Clinical and radiological features of Mycobacterium kansasii infection and Mycobacterium simiae infection. (2008) (42)
- Predictive value of specific risk factors, symptoms and signs, in diagnosing obstructive sleep apnoea and its severity (1994) (41)
- Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer. (2017) (41)
- Prevention and Early Detection for Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. (2019) (41)
- Unique volatolomic signatures of TP53 and KRAS in lung cells (2014) (40)
- Early detection and screening of lung cancer (2010) (37)
- Adenovirus Infection in Hospitalized Immunocompetent Children (2004) (36)
- Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). (2018) (36)
- Soluble triggering receptor expressed on myeloid cells-1 for distinguishing bacterial from aseptic meningitis in adults (2007) (35)
- OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer (2019) (34)
- Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. (2013) (33)
- From Expert Review of Molecular Diagnostics (2010) (32)
- Impaired Sleep Quality in Crohn’s Disease Depends on Disease Activity (2013) (32)
- The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell‐Free DNA in Advanced Lung Cancer (2018) (31)
- Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing (2016) (31)
- ESR/ERS statement paper on lung cancer screening (2020) (30)
- Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel (2005) (29)
- Volatile Organic Compounds in Exhaled Breath as Biomarkers for the Early Detection and Screening of Lung Cancer (2012) (29)
- Continuous Positive Airway Pressure for Motion Management in Stereotactic Body Radiation Therapy to the Lung: A Controlled Pilot Study. (2015) (29)
- Targeted Tissue and Cell‐Free Tumor DNA Sequencing of Advanced Lung Squamous‐Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations (2019) (29)
- Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors (2020) (29)
- Cancerous glucose metabolism in lung cancer—evidence from exhaled breath analysis (2016) (28)
- Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival (2019) (28)
- BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. (2018) (28)
- Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042 (2019) (28)
- Benzodiazepine and opioid sedation attenuate the sympathetic response to fiberoptic bronchoscopy. Prophylactic labetalol gave no additional benefit. Results of a randomized double-blind placebo-controlled study. (2008) (28)
- The QuantiFERON®-TB-GOLD Assay for Tuberculosis Screening in Healthcare Workers: A Cost-Comparison Analysis (2009) (28)
- Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report (2014) (27)
- Pulmonary Mycobacterium simiae infection: comparison with pulmonary tuberculosis (2008) (27)
- FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189 (2021) (27)
- Fecal Calprotectin as a Predictor of Abnormal Colonic Histology (2007) (26)
- Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors (2021) (25)
- Association of Elevated Levels of Vascular Endothelial Growth Factor in Obstructive Sleep Apnea Syndrome with Patient Age rather than with Obstructive Sleep Apnea Syndrome Severity (2006) (25)
- RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients (2017) (25)
- KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50% (2016) (24)
- Protective Effect of Immunosuppression on Granulation Tissue Formation in Metallic Airway Stents (2008) (24)
- Use of the 15-steps climbing exercise oximetry test in patients with idiopathic pulmonary fibrosis. (2008) (24)
- A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma (2017) (23)
- Cancer metabolism: the volatile signature of glycolysis—in vitro model in lung cancer cells (2017) (23)
- Prevention and Early Detection for NSCLC (23)
- The 15-step oximetry test: a reliable tool to identify candidates for lung transplantation among patients with idiopathic pulmonary fibrosis. (2009) (22)
- Infective endocarditis in diabetic and non-diabetic patients (2004) (22)
- Gender and lung cancer-SEER-based analysis. (2020) (22)
- Neonatal hyperbilirubinemia and glucose-6-phosphate dehydrogenase deficiency. (1973) (21)
- MA14.01 Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC) (2017) (20)
- ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question—to treat or not to treat? (2018) (20)
- Lung Cancer: A multidisciplinary Approach to Diagnosis and Management (2010) (20)
- Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma. (2014) (20)
- Familial Mediterranean Fever and Incidence of Cancer (2018) (20)
- Rapid Response to Larotrectinib (LOXO‐101) in an Adult Chemotherapy‐Naive Patients With Advanced Triple‐Negative Secretory Breast Cancer Expressing ETV6‐NTRK3 Fusion (2017) (19)
- Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study (2019) (18)
- Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 (2021) (18)
- Endobronchial drainage of lung abscess: The use of laser (2010) (16)
- The role of routine bronchoscopy for early detection of bronchial stump recurrence of lung cancer: 1 year post-surgery. (2009) (16)
- PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024 (2017) (16)
- Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer (2009) (15)
- Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC. (2018) (15)
- Mitochondrial induction as a potential radio-sensitizer in lung cancer cells - a short report (2015) (15)
- Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort (2019) (15)
- Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). (2020) (15)
- Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy (2016) (14)
- Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab (2017) (14)
- The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. (2021) (13)
- New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer (2016) (13)
- Automated 3‐dimensional morphologic analysis of sputum specimens for lung cancer detection: Performance characteristics support use in lung cancer screening (2015) (13)
- 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial (2020) (13)
- Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors (2019) (13)
- Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. (2016) (12)
- Impact of age on clinical features and outcome of infective endocarditis (2006) (12)
- Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. (2019) (11)
- Diagnostic value of complement components in pleural fluid: report of 135 cases. (2008) (11)
- Risk factors for death while awaiting lung transplantation in Israeli patients: 1997-2006. (2008) (11)
- Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases (2020) (11)
- UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN). (2021) (11)
- GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. (2020) (11)
- Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers (2021) (11)
- Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018 (10)
- A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance. (2015) (10)
- A retrospective six-year national survey of P. multocida infections in Israel (2009) (10)
- Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA (2019) (10)
- Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC) (2020) (10)
- Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options (2022) (9)
- HLA class II analysis in Jewish Israeli narcoleptic patients. (1995) (9)
- Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma (2019) (9)
- Stereotactic body radiotherapy for central lung tumors, yes we can! (2018) (9)
- 1313P Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC (2020) (9)
- Nocturnal carbon dioxide monitoring in patients with idiopathic intracranial hypertension (2013) (9)
- 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC (2022) (9)
- Associated Myocarditis: A Predictive Factor for Response? (2020) (9)
- Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer (2020) (8)
- MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts (2018) (8)
- Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC (2018) (8)
- Nivolumab induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy. (2021) (8)
- Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant. (2020) (8)
- Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort. (2019) (8)
- EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer (2014) (8)
- Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse (2020) (8)
- Screening for Lung Cancer: What Comes Next? (2015) (8)
- Right upper lobe 'window' in right main bronchus stenting. (2006) (8)
- Non-invasive early detection of malignant pulmonary nodules by FISH-based sputum test. (2018) (7)
- Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration. (2019) (7)
- An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer (2021) (7)
- Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers. (2017) (7)
- Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors (2021) (7)
- Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program (2022) (7)
- MA 02.06 BRAF Mutant NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy (2017) (7)
- Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers (2021) (7)
- Graft side-mismatching for single-lung transplantation does not affect outcomes: role of the pre-operative quantitative lung perfusion scan. (2008) (6)
- Insulin-like growth factor-1 receptor ( IGF-1 R ) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer (2014) (6)
- ST-segment depression during obstructive sleep apnea. (1994) (6)
- Benefits of Continuous Positive Airway Pressure (CPAP) During Radiation Therapy: A Prospective Trial. (2021) (6)
- Pharmacokinetics and Safety of Sublingual Flumazenil (CRLS035) in Healthy Adults (Potential Therapy for Hepatic Encephalopathy) (2014) (6)
- BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors (2021) (6)
- High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer (2018) (6)
- Are we facing a cure in lung cancer?-KEYNOTE-001 insights. (2019) (6)
- MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry (2018) (5)
- Better Selection Model for EML4-ALK Fusion Gene Test in Patients with Non-Small-Cell Lung Cancer (2013) (5)
- KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? (2018) (5)
- Abstract P6-20-02: Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers (2019) (5)
- Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT) (2021) (5)
- Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients (2022) (5)
- Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study (2021) (5)
- Short and long‐term usage of a dental device in sleep apnea syndrome (2009) (4)
- Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience (2022) (4)
- Real-world insights into patients with advanced NSCLC and MET alterations (2021) (4)
- Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents? (2020) (4)
- Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma) (2021) (4)
- Low-dose computed-tomography lung cancer screening: the first European recommendations from the European Society of Radiology and European Respiratory Society. (2015) (4)
- Lung cancer screening white paper: a slippery step forward? (2015) (4)
- O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC (2019) (3)
- Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients. (2018) (3)
- Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors (2021) (3)
- OA10.01 Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade (2017) (3)
- Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer (2018) (3)
- Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma. (2020) (3)
- 145P Impact of next-generation sequencing on survival in lung cancer (2018) (3)
- ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. (2019) (3)
- 0623 INCREASED RISK FOR CANCER IN YOUNG PATIENTS WITH SEVERE OBSTRUCTIVE SLEEP APNEA (2017) (3)
- Intensity‐modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma (2018) (3)
- Ethnic variation in toxicity and outcome of adjuvant chemoradiation for gastric cancer in Israel. (2013) (3)
- Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non‐small‐cell lung cancer (2020) (3)
- Determination of asthma control using administrative data regarding short-acting beta-agonist inhaler purchase (2018) (3)
- Clinical Presentation and Serial Lung Function (2015) (3)
- Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse. (2020) (3)
- Circulating ProGRP and tissue thyroid transcription factor 1 (TTF1) in small-cell lung carcinoma (SCLC) limited versus extensive stages. (2014) (3)
- FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC) (2022) (2)
- MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers (2017) (2)
- Sublingual Flumazenil for the Residual Effects of Hypnotics: Zolpidem and Brotizolam (2012) (2)
- Use of a nanoparticle-based artificial olfactory system, NaNose, to distinguish malignant from benign pulmonary nodules. (2010) (2)
- P3.03-022 Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement but Better Survival (2017) (2)
- [Recording nocturnal erections following injuries and insurance claims: cost-effectiveness]. (1999) (2)
- PUB137 Lung Cancer in Young Patients: Higher Rate of Driver Mutations, Brain Involvement and Better Survival (2017) (2)
- Lung cancer screening: a critical appraisal (2021) (2)
- [Insomnia in infancy and childhood--causes, significance, assessment and approach to treatment]. (1996) (2)
- Co-occurring genetic alterations in the RAS pathway promote resistance to MET inhibitor treatment in non-small cell lung cancer with a MET exon 14 skipping mutation (2018) (2)
- 1299P Real-world treatment patterns, clinical outcomes and EGFR/T790M testing practices in patients with EGFRm advanced NSCLC and 1L EGFR TKI therapy: A retrospective multinational study (REFLECT) (2020) (2)
- Non-small cell lung cancer PDL1 >50%—should we go single or combo? (2020) (2)
- OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data (2019) (2)
- KEYNOTE‐024 Update: Pembrolizumab vs Platinum‐Based Chemotherapy for Advanced NSCLC with PD‐L1 Tumor Proportion Score ≥50%: PS3 (2018) (2)
- P47.11 COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib (2021) (2)
- Case Presentation Alk Fusions Are Also Associated with Younger Age Next-generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib- Sensitive Alk Rearrangement in a Patient with Metastatic Non–small-cell Lung Cancer (2012) (2)
- P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC): Topic: IT (2017) (2)
- Anti‐PD‐1 antibodies in non‐small cell lung cancer (NSCLC): The real‐life setting experience: 181P (2016) (2)
- Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial (2020) (2)
- New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey (2018) (2)
- Breath analysis as a noninvasive biomarker for early detection of lung cancer. (2014) (2)
- MA01.01 Detection of Lung Cancer and EGFR Mutations by Electronic Nose System (2017) (2)
- Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study (2023) (2)
- Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report. (2022) (1)
- Free Communication Abstracts (2005) (1)
- Is ALK Inhibitor a Contraindication for Subsequent IVF Pregnancy? (2019) (1)
- Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity (2019) (1)
- P47.10 Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study (2021) (1)
- Local excision after neoadjuvant chemoradiation for rectal cancer: Is it an acceptable treatment option? (2010) (1)
- Liquid biopsy in the practice of neo-oncology. (2016) (1)
- Abstract 4490: Selinexor (KPT-330) radio-sensitizes non-small cell lung cancer cellsin vitroandin vivo (2015) (1)
- EP1.14-27 Retroperitoneal Pseudotumor Induced by Crizotinib Treatment for CMET ex14 Skip Mutation NCSLC (2019) (1)
- An outbreak of penicillin-resistant Neisseria gonorrhoea in southern Israel. (1991) (1)
- Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer (2022) (1)
- [LUNG CANCER TREATMENT IN 2015: ADVANCES AND FUTURE OUTLOOK]. (2015) (1)
- P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study (2018) (1)
- Increased Incidence of Lung Cancer Among Patients With Superficial Transitional Cell Carcinoma: A Potential Risk Cohort for Lung Cancer Screening. (2019) (1)
- [Ectopic pregnancy as a presenting symptom for lung cancer]. (2012) (1)
- Unusual Adverse Effects of Immune Checkpoint Inhibitors: Autonomic Neuropathy, Palmoplantar Keratoderma, Reiter Syndrome & Myasthenia Gravis: A Case Series and Review of the Literature (2020) (1)
- A36 Patient-Specific Humanized PDX Model for Overcoming Tumor Resistance to Immune Checkpoint Inhibitors in NSCLC Patients (2020) (1)
- Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP) (2016) (1)
- P1.01-039 Survival Impact of Next-Generation Sequencing in Lung Cancer (2017) (1)
- The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs) (2022) (1)
- Lung Cancer in Israel. (2020) (1)
- PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189 (2019) (1)
- Breath Analysis as a Non-invasive Biomarker for Early Detection of Lung Cancer (2014) (1)
- Metabolic modification as a potential therapeutics approach in lung cancer (2013) (1)
- Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer: The Davidoff Cancer Center Experience. (2020) (1)
- 7.1.1 Invited: Chemical Nanoarrays for Early Detection and Screening of Lung Cancer via Volatile Biomarkers (2012) (1)
- Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer (2020) (1)
- The Role of Routine Bronchoscopy for Early Detection of Bronchial Stump Recurrence of Lung Cancer – 1 Year Post Surgery. (2009) (1)
- P3.04-28 Can Ipilimumab Restore Immune Response in Advanced NSCLC After Progression on Anti PD1/PDL1 Agents? (2018) (1)
- Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025) - interim results (2016) (1)
- 399P Real-world insights into patients (pts) with advanced NSCLC and MET alterations (2020) (1)
- Carpal Tunnel Syndrome as an Unusual Immune Checkpoint Inhibitor Adverse Effect: A Case Series and Review of the Literature (2020) (1)
- P1.04-47 Tumor Mutation Burden Through Hybrid Capture – Circulating Tumor DNA May Predict Response to Immunotherapy in NSCLC (2019) (1)
- Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing (2022) (1)
- Comprehensive genomic profiling of 298 lung cancers of varying histologies harboring MET exon 14 alterations. (2016) (1)
- Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage Therapy (2021) (1)
- Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer (2020) (1)
- 10P The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact (2018) (1)
- Detection of glucose-6-phosphate dehydrogenase deficiency in the newborn using blood specimens dried on filter paper. (1973) (1)
- [Antenatal follow-up and the attitude to a newborn of a mother with a positive VDRL test]. (2001) (1)
- P2.03b-047 The Clinical Impact of Multiplex ctDNA Gene Analysis in Lung Cancer: Topic: Biomarkers (2017) (1)
- Abstract 2075: Combination tTerapy KPT-SINE (selective inhibitors of nuclear export) with radiotherapy have additive effects in non-small cell lung cancer (NSCLC) cellsin vitroandin vivo. (2013) (1)
- Retroperitoneal Pseudotumor Induced by Crizotinib Treatment for c-MET exon 14 Skip Mutation NCSLC. (2019) (1)
- 126PThe clinical impact of multiplex ctDNA gene analysis in lung cancer (2017) (0)
- Immunohistochemistry detection of epidermal growth factor receptor (EGFR) exons 19 and 21 mutations in non-small cell lung cancer (NSCLC) using novel mutation specific antibodies. (2010) (0)
- P3.04-11 The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) (2018) (0)
- Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literature. (2023) (0)
- Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP) (2019) (0)
- 951P Induction osimertinib followed by definitive sequential radiation therapy and/or surgery in unresectable EGFR-mutant stage III NSCLC: An open-label, single-arm, phase II study (2022) (0)
- Successful Treatment of a Complex Paraneoplastic Neurological Syndrome in a Patient with Metastatic Breast Cancer (2022) (0)
- Real-world outcomes and clinical characteristics of patients with brain metastases from EGFR mutated non-small cell lung cancer: Data from a large retrospective study (REFLECT). (2021) (0)
- Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases: 182P (2016) (0)
- P3.03-15 Lung Cancer Regulation of Glucose Metabolic Stress Response (2018) (0)
- Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study (2019) (0)
- Erratum: Screening for lung cancer: Time for large-scale screening by chest computed tomography (European Respiratory Journal (2014) 44 (217-238) DOI: 10.1183/09031936.00164513) (2019) (0)
- P3.03-040 Long Term Outcomes Following IMRT for Mesothelioma Post EPP and Unresectable: Topic: Mesothelioma Clinical (2017) (0)
- [THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER]. (2017) (0)
- Lung Cancer Detection with LuCED, a Novel Test Based on 3D Cytometry of Sputum Cells (2014) (0)
- Lung Cancer Prevention (2010) (0)
- EP1.12-01 Does PCI Still Have a Role in Limited SCLC? (2019) (0)
- The influence of circulating tumor DNA analysis on response to immunotherapy in non‐small cell lung cancer (NSCLC): 67P (2018) (0)
- O330 Predicting Clostridium difficile toxin in hospitalised patients with antibiotic-associated diarrhoea (2007) (0)
- In Reply. (2015) (0)
- MA13.05 Nivolumab in Non-Small Cell Lung Cancer (NSCLC): The Real-Life Data (2017) (0)
- 1147P AI-based detection of molecular biomarkers directly from H&E scanned slide (2021) (0)
- Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence (2020) (0)
- Omission of Prophylactic Cranial Irradiation in the Management of Limited-Stage Small-Cell Lung Cancer: Is that Ready for Prime-Time? An International Survey (2021) (0)
- MA 18.11 High Incidence of Lung Cancer in Early Stage TCC Patients (2017) (0)
- Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity (2019) (0)
- 10: Volatile biomarkers for discrimination of lung cancer risk and mutation (2015) (0)
- Abstract LB-041: Novel platform to profile variants of uncertain significant (VUS) with preliminary retrospective clinical validation in non-small cell lung cancer (NSCLC) (2017) (0)
- Stereotactic body radiotherapy for central lung tumors, yes we can! (2018) (0)
- 115PKIF5B & CCDC6 RET IN LUNG CANCER: CLINICAL INSIGHTS AND RESPONSE TO PERSONALIZED BASED THERAPY (2015) (0)
- 1173P Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC (2021) (0)
- NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs (2022) (0)
- Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi). (2018) (0)
- P84.10 The Impact of 3rd-Line ALK Inhibitors in ALK Positive NSCLC in Real-World Data (2021) (0)
- P13.10 Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases (2016) (0)
- Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025): Interim results. (2016) (0)
- Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types. (2019) (0)
- KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? (2018) (0)
- Abstract 491: Salvage MET amplification detection and therapy through cell-free DNA NGS in a progressing lung cancer patient (2016) (0)
- Identification of asthma level of control using administrative data of short-acting beta-agonist inhalers purchase (2016) (0)
- 133TiP Neoadjuvant osimertinib followed by sequential definitive radiotherapy and/or surgery in stage III EGFR-mutant NSCLC: An open-label, single-arm, phase II study (2023) (0)
- Development of Pericardial Effusion in Non-small Cell Lung Cancer Is Associated with the Presence of EGFR/ALK Mutations. (2022) (0)
- Assembly 11: thoracic oncology (2018) (0)
- Cardiomyopathy Etiologies, Symptoms and Management (2021) (0)
- ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy? (2020) (0)
- Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience. (2019) (0)
- P3.11-22 The Path to National Lung Cancer Screening Program in Israel (2018) (0)
- KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. (2022) (0)
- P2.07-048 Immunotherapy vs. Targeted Therapy - Who Wins? A Case Series (2017) (0)
- 42P Is there a delay in diagnosis of lung cancer in women (2018) (0)
- The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. (2023) (0)
- Glycolytic phenotype mapping in lung cancer cell lines (2012) (0)
- 1351P The impact of BRCA mutation status on NSCLC disease course and response to therapy (2020) (0)
- Abstract B26: NSCLC personalized medicine via integration into biomathematical model individual clinical data and prognostic/predictive biomarkers (2012) (0)
- Abstract 5394: The clinical impact of multiplex ctDNA gene analysis in lung cancer (2017) (0)
- Are all RET fusions NSCLC alike? Clinical pitfalls and response to targeted therapy: KIF5B vs. CCDC6. (2015) (0)
- Neoadjuvant osimertinib followed by sequential definitive radiotherapy and/or surgery in stage III EGFR-mutant NSCLC: An open-label, single-arm, phase II study. (2023) (0)
- Central nervous system (CNS) metastases remain a significant problem in the management of patients with ALK-rearranged non-small cell lung cancer (NSCLC) (2018) (0)
- Abstract 1831: Selective inhibitors of nuclear export (SINE) induce multiple tumor suppressor proteins (TSP) activity and show single agent antitumor effect and synergy with Bcl-2 antagonist in non-small cell lung cancer (2012) (0)
- Lung cancer early detection via breath analysis (2015) (0)
- P1.13-33 Ex Vivo 2*2*2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer (2018) (0)
- 68PCirculating tumor cells spillage after lung nodule biopsy (2017) (0)
- Landscape of genomic alterations (GA) detected by next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) adenocarcinoma in Israel. (2014) (0)
- P2.03b-042 MET exon 14 Mutations Encode a Hyperactive Kinase and Therapeutic Target in Lung Adenocarcinoma (2017) (0)
- [Preparing children for anesthesia and surgery]. (1988) (0)
- P1.01-027 Increased Risk of Lung Cancer among Women with Superficial TCC: A Potential Risk Cohort for Lung Cancer Screening: Topic: Lung Cancer Screening, Diagnosis (2017) (0)
- 146P The clinical impact of comprehensive cfDNA genomic testing in lung cancer (2018) (0)
- Rapid functional assay to elucidate the oncogenic activity of unknown mutations (variants of unknown significance). (2015) (0)
- Mitochondrial induction as a potential radio-sensitizer in lung cancer cells - a short report (2015) (0)
- Oral Scientific SessionContinuous Positive Airway Pressure (CPAP) for Motion Management in Stereotactic Body Radiation Therapy (SBRT) to the Lung: A Controlled Pilot Study (2015) (0)
- P3.01-28 The Clinical Impact of Comprehensive cfDNA Genomic Testing in Lung Cancer (2018) (0)
- Prognostic impact of first treatment choice in EGFR mutant non-small cell lung cancer (mNSCLC) patients (pts) per mutation type; retrospective analysis. (2015) (0)
- Economic aspects of nivolumab in non-small cell lung cancer (NSCLC): Lessons from real life. (2017) (0)
- P3.07-007 Compassionate Use Program for New Cancer Drugs in Israel - Shortcut for Reimbursement Approval: Topic: Therapy and Economics (2017) (0)
- Abstract A018: Patient-derived xenograft (PDX) models of NSCLC reflect clinical drug responses and predict effective treatments for patients (2018) (0)
- The diagnostic puzzle of ALK rearrangement in lung cancer. A novel intron related abnormality (2013) (0)
- Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer (2013) (0)
- P3.01-060 The Clinical Utility of ctDNA Gene Analysis in Lung Cancer (2017) (0)
- DIAGNOSIS OF PULMONARY PATHOLOGY IN HEMODIALYSIS PATIENTS USING A COMBINATION OF IMAGING AND LUNG FUNCTION TESTS (2007) (0)
- LUNG TRANSPLANTATION raft Side-mismatching for Single-lung Transplantation Does Not ffect Outcomes : Role of the Pre-operative Quantitative Lung erfusion Scan (2008) (0)
- [Azithromycin as a novel treatment for bronchiolitis obliterans syndrome]. (2007) (0)
- EP08.02-047 The Impact of CGP on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs (2022) (0)
- Reply (2018) (0)
- Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib (2023) (0)
- RECIST measurement through the exhaled breath in lung cancer: Myth or reality? (2014) (0)
- What's Common Is Common - Well Not This Time: A Case of Primary Lung Adenocarcinoma in a 15-Year-Old Girl (2022) (0)
- Abstract LB-B24: Identification of the functional significance of mutations using the novel Precision Cancer Analysis System (2015) (0)
- Abstract A36: Breath Biomarkers in the Post NLST-era for the Discrimination between Malignant from Benign Pulmonary Nodules (2012) (0)
- Prophylactic treatment for acneiform rash caused by EGFR inhibitors: Prospective randomized double-blind trial comparing daily topical chloramphenicol 3% plus prednisolone 0.5% vs chloramphenicol 3% vs aqua cream. (2018) (0)
- Identification of the functional significance of mutations using the novel Precision Cancer Analysis System: 64P (2016) (0)
- Functional characterization of mutations and their interaction using the novel functional annotation for cancer treatment (FACT) platform (2016) (0)
- Health‐Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non‐Squamous NSCLC: KEYNOTE‐189: PD.1.01 (2018) (0)
- Journal Pre-proof UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN) Real-life (2022) (0)
- Abstract 2240: A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS (2016) (0)
- The art of detecting EML4-ALK gene rearrangements in NSCLC patients - Immediate implications for patient care (2013) (0)
- Automated target-FISH lung cancer detection (LCD) test of induced sputum (2015) (0)
- Prevalence of Sleep Disturbances in Patients With Crohn's Disease (CD) – A Comparative Study (2011) (0)
- MA06.05 The Micro-Environmental Cross Talk Between Mast Cells and Lung Cancer Cells Through Cell-to-Cell Contact (2018) (0)
- The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact. (2019) (0)
- P1.04-30 A Potential Effect of Diabetes Mellitus and Metformin Use on Efficacy of Immune Checkpoint Inhibitors (ICI) (2018) (0)
- P3.13-030 Metabolic Parameters of FDG PET at Early Evaluation of NSCLC Differ with Histological Subtypes (2017) (0)
- P2.14-64 Is ALK Inhibitor a Contraindication for Subsequent IVF Pregnancy? (2019) (0)
- Chapter 29: Classification of Lung Cancer Histology by Gold Nanoparticle Sensors (2017) (0)
- OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer (2022) (0)
- LYMPHANGIOLEIOMYOMATOSIS IN ISRAEL (2008) (0)
- The current and future revolution in lung cancer screening and management (2020) (0)
- ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data (2022) (0)
- 15P FGFR3-TACC3 fusion (F) as an acquired resistance mechanism following treatment with EGFR TKIs and a suggested novel target in aNSCLC (2021) (0)
- Abstract 1379: Identification of the functional significance of mutations using the novel precision cancer analysis system (2016) (0)
- The clinical utility of next‐generation sequencing in lung cancer: 152P (2016) (0)
- P2.12-14 Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer. (2018) (0)
- P2.03b-033 Clinical Effectiveness of Hybrid Capture-Based Massive Parallel Sequencing in Therapeutic Strategy Planning in Lung Cancer: Topic: Biomarkers (2017) (0)
- Iconographies supplémentaires de l'article : Use of the 15-steps climbing exercise oximetry test in patients with idiopathic pulmonary fibrosis (2011) (0)
- EP1.11-21 Lung Cancer Screening Pilot in Israel (2019) (0)
- New ARCHITECT plasma pro-gastrin-releasing peptide assay and lung cancer: Implications for diagnosis, follow-up, and prognosis. (2015) (0)
- Prognostic factors for tumor histological response to preoperative chemoradiation in rectal cancer (2008) (0)
- DRB1*1502-DQB1*0601-DQA1*0103 and DRB1*04-DQB1*0302 in Jewish hypersomnolent patients. (2002) (0)
- EP08.02-122 Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP) (2022) (0)
- Title: Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer (2019) (0)
- P84.03 GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients (2021) (0)
- P3.02-096 The Interaction Between Mast Cells and Lung Cancer Cells Through Extracellular Vesicles (2017) (0)
- Identification of the functional significance of mutations using the novel Precision Cancer Analysis System. (2015) (0)
- Benefits of Continuous Positive Airway Pressure (CPAP) in Radiotherapy: A Prospective Trial (2019) (0)
- Keratoderma as a Paraneoplastic Sign on NSCLC Patient - Case Report (2018) (0)
- Intracranial activity of crizotinib: something to rely on? (2016) (0)
- P3.07-004 Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data: Topic: Therapy and Economics (2017) (0)
- PO-0657: A prospective trial evaluating continuous positive airway pressure on tumor and organ motion and dose during SBRT (2015) (0)
- [Primary iliopsoas abscess in children]. (1990) (0)
- P76.57 Resistance Mechanisms to Osimertinib Upon it’s Line of Therapy in Patients with EGFR+ NSCLC and Beyond (2021) (0)
- P1.04-17 Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients with Metastatic Non-Small-Cell Lung Cancer (2018) (0)
- P3.01-056 Intracranial Activity of Osimertinib in Naïve EGFRm T790M(-)And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases (2017) (0)
- Increasederythrocyteadhesivenessandaggregation in obstructive sleep apnea syndrome (2007) (0)
- P3.02c-053 Clinical and Plasma Biomarkers for Disease Control with Nivolumab Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC): Topic: IT (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Nir Peled?
Nir Peled is affiliated with the following schools:
